All In Biotech

Drug Trial Radar · NCT06170476

A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in PONV

A Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study of HSK21542 Injection for the Prevention of Postoperative Nausea and Vomiting (PONV)

Last checked: Nov 20, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Nov 10, 2023

Primary completion

Feb 28, 2024

Study completion May 15, 2024

Sponsor

Lead sponsor
Sichuan Provincial People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Dose-Finding study. About 200 subjects undergoing elective laparoscopic abdominal or gynecological surgery are planned to be enrolled and randomized into four groups by a ratio of 1:1:1:1.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

  • HSK21542-60μgDrug

    HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

  • HSK21542-120μgDrug

    HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

  • HSK21542-180μgDrug

    HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

  • PlaceboDrug

    A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete responseTime frame: 24 hours after the end of surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.